Category: MS Drug Therapies

Novartis update on FDA review of ofatumumab, a self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis

Basel, June 2, 2020 —  Novartis today announced that it has received notice from the US Food and Drug Administration (FDA)…

Stuart Schlossman

Drugs in Development for MS, Including Ofatumumab (with MS Neurology experts Lublin; Bar-Or; Calabresi; Coyle and Krieger)

This NeurologyLive Peer Exchange, “Advances in Early Treatment Approaches in Multiple Sclerosis,” includes insight from Fred D. Lublin, MD; Amit Bar-Or, MD, FRCP;…

Stuart Schlossman

Response to Cladribine Tablets in RRMS

Click HERE to Subscribe for the MS Beacon Newsletter ““““““““““““““ Jeffrey M. Kaplan, MD, and Matthew J. Baker, MD, discuss…

Stuart Schlossman

Ocrelizumab Compared to Glatiramer Acetate and Dimethyl Fumarate for MS

Jul 02, 2020 — Mark Freedman, MD, outlines a retrospective trial presented at the Consortium of Multiple Sclerosis Centers (CMSC)…

Stuart Schlossman

Short-Commitment Dosing Regimen Gives Cladribine An Advantage in MS

Click HERE to Subscribe for the MS Beacon Newsletter The professor of clinical neurology, and director of the MS Division…

Stuart Schlossman

NICE Does Not Favor Adding Mayzent to NHS England for Active SPMS

If you think you have been exposed to COVID‑19 and develop a fever and symptoms, such as cough or difficulty…

Stuart Schlossman

Study finds no link between DMTs and Covid-19 severity

Source: Centers for Disease Control and Prevention        –  Stay Healthy, Stay Home and Wash Your Hands Click HERE to…

Stuart Schlossman

Bristol Myers Squibb Announces Commercial Launch and Availability of ZEPOSIA® (ozanimod), a New Oral Treatment for Relapsing Forms of Multiple Sclerosis

Stay Healthy, Stay Home and Wash Your Hands Click HERE to Subscribe for the MS Beacon Newsletter ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ Press Release…

Stuart Schlossman

What is the Future of MS Therapy? Neuroprotection, and Blurred Lines Between Disease Phenotypes

When Ben Greenberg, MD, MPH, was asked to present a talk for the 2020 Consortium of Multiple Sclerosis Centers (CMSC)…

Stuart Schlossman

Siponimod Reduces Risk of Disability Progression Regardless of Prior Relapses in MS

Data from the phase 3 EXPAND clinical trial (NCT01665144) of siponimod (Mayzent; Novartis) demonstrated the treatment’s ability to reduce the…

Stuart Schlossman

Categories

Latest Blog Posts